Latest RNS10 Apr 2019 15:57
I like the incentive conditions:
1) When the Company has signed out-licensing deal(s) for any of its technologies or programmes which, together with other financial resources, provides sufficient funding to allow the achievement of clinical proof of concept data for the CTX and hRPC programmes, one third of the options will vest.
2) When the Company's share price has doubled from the price at the date of grant, one third of the options will vest.
3) When the sixth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest.